Biphosphonates

Archives of Disease in Childhood

Volumn 76, Issue 1, 1997, Pages 73-75

  Allgrove, Jeremy ^a  

^a NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE DEFORMATION; BONE MATRIX; BONE MINERAL; BONE PAIN; BONE TURNOVER; CALCIFICATION; CHILD; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

EID: 0031018362     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.76.1.73     Document Type: Short Survey

References (28)

1. Tsuchimoto M, Azuma Y, Higuchi O, et al. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 1994;66:25-33
2. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985;61:952-6.
3. Van Persyn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992;184: 249-54.
4. Allgrove J. Bisphosphonates: paediatric indications - advantages and possible side-effects. Proceedings - paediatric osteology. New developments in diagnosis and therapy. Cologne, Germany, 5-7 October 1995. Excerpta Medica International Congress Series No 1105. Amsterdam: Elsevier, 1996:261-73.
5. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:360-3.
6. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988;8:71-2.
7. Harinck HI, Bijvoet OL, van der Meer JW, Jones B, Onvlee GJ. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet 1984;i:513.
8. Bembi B, Agosti E, Boehm P, Nassimbeni G, Zanatta M, Vidoni L. Aminohydroxypropylidene-bisphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr 1994;83:122-4.
9. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA. Aminohydroxypropylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 1994;94:385-9.
10. Cassinelli HR, Mautalen CA, Heinrich JJ, Miglietta A, Bergada C. Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone and Mineral 1992;19:175-84.
11. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-4.
12. McIntyre HD, Cameron DP, Urquhart SM, Davies WE. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 1989;65:244-6.
13. Varache N, Audran M, Clochon P, et al. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Clin Rheumatol 1991;10:328-32.
14. Shaw NJ, White CP, Fraser WD, Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child 1994;71:235-8.
15. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9(suppl 6):33-5.
16. Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 1990;4:510-1
17. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE. Severe immobilization-induced hypercalcaemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 1994;57:301-3.
18. Bishop NJ, Williams DM, Compston JC, Stirling DM, Prentice A. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol 1995;89:927-8.
19. Yamaguchi K, Grant J, Noble-Jamieson G, Jamieson N, Barnes ND, Compston JE. Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. Bone 1995;16:61-7.
20. Rawlinson PS, Green RH, Coggins AM, Boyle IT, Gibson BE. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation. Arch Dis Child 1991;66:638-9.
21. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. Diphosphonates in the treatment of myositis ossificans. Lancet 1969;ii:845.
22. Rogers JG, Dorst JP, Geho WB. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr 1977;91:1011-4.
23. Meradjii M, De Villeneuve VH, Huber J, De Bruin WC, Pearse RG. Idiopathic arterial calcification in siblings: radiological diagnosis and successful treatment. J Pediatr 1978;92:401-5.
24. Vera J, Lucaya J, Garcia Conesa JA, Aso C, Balaguer A. Idiopathic infantile arterial calcification: unusual features. Pediatr Radiol 1990;20:585-7.
25. Thiaville A, Smets A, Clerex A, Perlmutter N. Idiopathic infantile arterial calcification: a surviving patient with renal artery stenosis. Pediatr Radiol 1994;24:506-8.
26. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 1995;34:68-77.
27. Chines A, Petersen DJ, Schranck FW, Whyte MP. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 1991;119:51-7.
28. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220-4.